rofecoxib has been researched along with Cardiovascular Diseases in 147 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer." | 9.12 | Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 7.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| " We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer." | 5.12 | Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 3.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| "It can be postulated that in addition to the risk of heart attack and stroke, rofecoxib users were at increased risk of hemorrhage, in addition to other thrombotic and embolic adverse events, which was exacerbated in those taking blood thinners or NSAIDs." | 3.75 | Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. ( Barry, WT; Bottone, FG, 2009) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors ('statins') and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') and increase in cardiovascular risk." | 3.74 | Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. ( Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "Rofecoxib (Vioxx) was withdrawn from the market because of increased death from cardiovascular (CV) events." | 2.43 | Cardiovascular issues of COX-2 inhibitors and NSAIDs. ( Chowienczyk, P; Kirkham, B; Wong, M, 2005) |
| "Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1." | 2.43 | Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. ( Henry, D; McGettigan, P, 2006) |
| " Indeed, both observational studies and randomised clinical trials showed that rofecoxib is associated with a significantly increased risk of acute myocardial infarction in patients receiving either high daily dosage (>25 mg/day) or for a long period of time (> 18 months)." | 2.42 | [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. ( Scheen, AJ, 2004) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| " Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy." | 2.41 | Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002) |
| "The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has been disappointing." | 1.35 | Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. ( Aiyar, N; Behm, DJ; Bentley, RG; Coatney, RW; Doe, CP; Eybye, ME; Maniscalco, K; Olzinski, AR; Westfall, TD; Willette, RN; Zhao, S, 2009) |
| "Rofecoxib was withdrawn from the market worldwide because of concerns relating to cardiovascular safety." | 1.33 | Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. ( Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J, 2005) |
| " Data on duration, dosage and indications were taken from the rofecoxib prescriptions." | 1.33 | [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences]. ( van der Veen, WJ; van der Werf, GT, 2006) |
| "Rofecoxib was recalled in September 2004 when studies identified increased cardiovascular risk compared with placebo among patients taking rofecoxib." | 1.33 | The patient's perspective on the recall of Vioxx. ( Hawker, GA; Katz, JN; Solomon, DH, 2006) |
| " In addition, the cardiac toxicity of rofecoxib could be due to its unique chemical structure, its pharmacokinetics and tissue distribution, and/or the presence of toxic metabolites." | 1.32 | COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. ( Davies, NM; Jamali, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 137 (93.20) | 29.6817 |
| 2010's | 9 (6.12) | 24.3611 |
| 2020's | 1 (0.68) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, TT | 1 |
| Solomon, DH | 2 |
| Kesselheim, AS | 1 |
| Moore, N | 2 |
| Miyajima, A | 1 |
| Okamoto, M | 1 |
| Muto, T | 1 |
| Hirota, T | 1 |
| McIntyre, WF | 1 |
| Evans, G | 1 |
| Anwar, A | 1 |
| Anwar, IJ | 1 |
| Delafontaine, P | 1 |
| Sobel, M | 1 |
| Madigan, D | 3 |
| Wang, W | 1 |
| Motola, D | 1 |
| Vargiu, A | 1 |
| Leone, R | 1 |
| Conforti, A | 1 |
| Moretti, U | 1 |
| Vaccheri, A | 1 |
| Velo, G | 1 |
| Montanaro, N | 1 |
| Jaksch, W | 1 |
| Dejaco, C | 1 |
| Schirmer, M | 1 |
| Setakis, E | 1 |
| Leufkens, HG | 2 |
| van Staa, TP | 1 |
| Baron, JA | 2 |
| Sandler, RS | 2 |
| Bresalier, RS | 2 |
| Lanas, A | 2 |
| Morton, DG | 1 |
| Riddell, R | 2 |
| Iverson, ER | 1 |
| Demets, DL | 1 |
| Bottone, FG | 1 |
| Barry, WT | 1 |
| Willette, RN | 1 |
| Eybye, ME | 1 |
| Olzinski, AR | 1 |
| Behm, DJ | 1 |
| Aiyar, N | 1 |
| Maniscalco, K | 1 |
| Bentley, RG | 1 |
| Coatney, RW | 1 |
| Zhao, S | 1 |
| Westfall, TD | 1 |
| Doe, CP | 1 |
| Simon, LS | 2 |
| White, WB | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 1 |
| Chung, CP | 1 |
| Castellsague, J | 1 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Hsiao, FY | 2 |
| Tsai, YW | 2 |
| Huang, WF | 2 |
| Liu, JY | 1 |
| Li, N | 2 |
| Yang, J | 1 |
| Qiu, H | 1 |
| Ai, D | 1 |
| Chiamvimonvat, N | 1 |
| Zhu, Y | 1 |
| Hammock, BD | 1 |
| Ross, JS | 2 |
| Konstam, MA | 4 |
| Egilman, DS | 2 |
| Krumholz, HM | 2 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Sigelman, DW | 1 |
| Mayer, JW | 1 |
| Furberg, CD | 3 |
| Avorn, J | 2 |
| Jaeschke, R | 1 |
| Gajewski, P | 1 |
| Brozek, J | 1 |
| Zhao, SZ | 1 |
| Burke, TA | 1 |
| Whelton, A | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Sonnenblick, EH | 1 |
| Höcherl, K | 1 |
| Dreher, F | 1 |
| Kurtz, A | 1 |
| Bucher, M | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 2 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 1 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| James, MJ | 1 |
| Cleland, LG | 1 |
| Krum, H | 1 |
| Liew, D | 1 |
| Aw, J | 1 |
| Haas, S | 1 |
| Fitzgerald, GA | 3 |
| Adams, D | 1 |
| Langton, PE | 1 |
| Hankey, GJ | 1 |
| Eikelboom, JW | 1 |
| Egan, KM | 1 |
| Lawson, JA | 1 |
| Fries, S | 1 |
| Koller, B | 1 |
| Rader, DJ | 1 |
| Smyth, EM | 1 |
| Kondro, W | 1 |
| Frantz, S | 1 |
| Bijlsma, JW | 1 |
| Zierenberg, O | 1 |
| Lenzer, J | 1 |
| Strand, V | 1 |
| Håkansson, J | 1 |
| Rosenberg, P | 1 |
| Davies, NM | 1 |
| Jamali, F | 1 |
| Couzin, J | 3 |
| Oakley, G | 1 |
| Juhlin, R | 1 |
| Scheen, AJ | 1 |
| Kim, PS | 1 |
| Reicin, AS | 2 |
| Villalba, L | 1 |
| Witter, J | 1 |
| Wolfe, MM | 1 |
| Hedner, T | 1 |
| Melander, A | 1 |
| Hansen, PR | 1 |
| Callréus, T | 1 |
| Meyer, CH | 1 |
| Berenbaum, F | 1 |
| Wardle, EN | 1 |
| Kamen, B | 1 |
| Kieran, M | 1 |
| Senior, K | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Morton, D | 1 |
| Psaty, BM | 1 |
| Drazen, JM | 2 |
| Giannitsis, E | 1 |
| Arellano, FM | 1 |
| Weinberg, JM | 1 |
| Rawson, NS | 1 |
| Nourjah, P | 1 |
| Grosser, SC | 1 |
| Graham, DJ | 1 |
| Smith, ER | 1 |
| Weatherall, M | 1 |
| Aldington, S | 1 |
| Shirtcliffe, P | 1 |
| Caldwell, B | 1 |
| Beasley, R | 1 |
| Jerie, P | 1 |
| Laible, B | 1 |
| Okie, S | 1 |
| Eisenberg, RS | 1 |
| Evensen, S | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Maloney, DM | 1 |
| Harrison-Woolrych, M | 1 |
| Herbison, P | 1 |
| McLean, R | 1 |
| Ashton, J | 1 |
| Slattery, J | 1 |
| Bolten, WW | 1 |
| Reiter, S | 1 |
| Fortun, PJ | 1 |
| Hawkey, CJ | 3 |
| Florentinus, SR | 1 |
| Heerdink, ER | 1 |
| de Boer, A | 1 |
| van Dijk, L | 1 |
| Braunstein, N | 1 |
| Polis, A | 1 |
| Brophy, JM | 1 |
| Khamsi, R | 1 |
| Manthous, CA | 1 |
| Daikh, DI | 1 |
| Messerli, FH | 1 |
| Sichrovsky, T | 1 |
| Frazier, KC | 1 |
| Araujo, LF | 1 |
| Soeiro, Ade M | 1 |
| Fernandes, Jde L | 1 |
| Serrano Júnior, CV | 1 |
| Bobadilla, RV | 1 |
| Barnett, EM | 1 |
| Randels, CL | 1 |
| Wong, M | 1 |
| Chowienczyk, P | 1 |
| Kirkham, B | 1 |
| Rainsford, KD | 1 |
| Wadman, M | 2 |
| Wu, R | 1 |
| Laplante, MA | 1 |
| de Champlain, J | 1 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Bombardier, C | 2 |
| Laine, L | 2 |
| Burgos-Vargas, R | 2 |
| Davis, B | 2 |
| Day, R | 2 |
| Ferraz, MB | 2 |
| Hochberg, MC | 2 |
| Kvien, TK | 2 |
| Schnitzer, TJ | 2 |
| Weaver, A | 1 |
| Guo, ZR | 1 |
| Wen, YW | 1 |
| Shih, YT | 1 |
| Dogné, JM | 1 |
| Hanson, J | 1 |
| Supuran, C | 1 |
| Pratico, D | 1 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Sooriakumaran, P | 1 |
| Nelson, NJ | 1 |
| van der Veen, WJ | 1 |
| van der Werf, GT | 1 |
| Hawker, GA | 1 |
| Katz, JN | 1 |
| Nissen, SE | 1 |
| Motsko, SP | 1 |
| Rascati, KL | 1 |
| Busti, AJ | 1 |
| Wilson, JP | 1 |
| Barner, JC | 1 |
| Lawson, KA | 1 |
| Worchel, J | 1 |
| Armstrong, D | 1 |
| Williams, D | 1 |
| Singh, M | 1 |
| Hind, C | 1 |
| McGettigan, P | 1 |
| Henry, D | 1 |
| Marwali, MR | 1 |
| Mehta, JL | 1 |
| Mühlbauer, B | 1 |
| Timm, J | 1 |
| Scharnetzky, E | 1 |
| Andersohn, F | 1 |
| Schill, W | 1 |
| Garbe, E | 1 |
| Pigeot, I | 1 |
| Höer, A | 1 |
| Häussler, B | 1 |
| Usher, C | 1 |
| Bennett, K | 1 |
| Teeling, M | 1 |
| Feely, J | 1 |
| Sibilia, J | 1 |
| Deray, G | 3 |
| Montalescot, G | 1 |
| Valat, JP | 2 |
| Héloire, F | 2 |
| Zarraga, IG | 1 |
| Schwarz, ER | 1 |
| Presler, AH | 1 |
| Jugdutt, BI | 1 |
| Ashworth, AJ | 1 |
| Tabrizchi, R | 1 |
| Depont, F | 1 |
| Fourrier, A | 1 |
| Merlière, Y | 1 |
| Droz, C | 1 |
| Amouretti, M | 1 |
| Bégaud, B | 1 |
| Bénichou, J | 1 |
| Moride, Y | 1 |
| Velo, GP | 1 |
| Sturkenboom, M | 1 |
| Blin, P | 1 |
| Hellstrom, HR | 1 |
| Salzberg, DJ | 1 |
| Weir, MR | 2 |
| Kerr, DJ | 1 |
| Dunn, JA | 1 |
| Langman, MJ | 1 |
| Smith, JL | 1 |
| Midgley, RS | 1 |
| Stanley, A | 1 |
| Stokes, JC | 1 |
| Julier, P | 1 |
| Iveson, C | 1 |
| Duvvuri, R | 1 |
| McConkey, CC | 1 |
| Martínez-González, J | 1 |
| Badimon, L | 1 |
| Vinsonneau, U | 1 |
| Brondex, A | 1 |
| Mansourati, J | 1 |
| Saraux, A | 1 |
| Cornily, JC | 1 |
| Arlès, F | 1 |
| Godon, P | 1 |
| Quiniou, G | 1 |
| Sukel, MP | 1 |
| van der Linden, MW | 1 |
| Chen, C | 1 |
| Erkens, JA | 1 |
| Herings, RM | 1 |
| Mayer, TV | 1 |
| Reicin, A | 2 |
| Shapiro, D | 3 |
| Stienburg, KL | 1 |
| Patrono, C | 2 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Gotlieb, D | 1 |
| Comarow, A | 1 |
| Sperling, RS | 2 |
| Barr, E | 2 |
| Gertz, BJ | 1 |
| Yu, Q | 1 |
| Sharma, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Phase III, Randomized, Double Blind, Placebo Controlled Study of Rofecoxib in Colorectal Cancer Patients Following Adjuvant Chemotherapy[NCT00031863] | Phase 3 | 0 participants | Interventional | 2001-02-28 | Completed | ||
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500] | Phase 4 | 24 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
37 reviews available for rofecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I | 2020 |
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; | 2015 |
4 years after withdrawal of rofecoxib: where do we stand today?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase | 2008 |
COX-2 selective inhibitors and heart health.
Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; | 2005 |
Differences between COX-2-specific inhibitors: clinical and economic implications.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2002 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as To | 2004 |
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2004 |
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardio | 2005 |
[COX-2 inhibitors--one step forward and two steps back].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Life after Vioxx: the clinical implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Tr | 2005 |
The safety of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Case-Control Studi | 2005 |
Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cycloox | 2005 |
[Cardiovascular events: a class effect by COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
COX-2 inhibitors and the heart: putting risk in perspective.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Protocols; Cyclooxygenase | 2005 |
Introduction - The coxib controversies.
Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones | 2005 |
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclo | 2005 |
Coxibs and cardiovascular side-effects: from light to shadow.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2006 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
COX-2 inhibitors and the heart: are all coxibs the same?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Coxibs and heart disease: what we have learned and what else we need to know.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2007 |
What have we learnt from Vioxx?
Topics: Cardiovascular Diseases; Compensation and Redress; Cyclooxygenase 2 Inhibitors; Drug Industry; Human | 2007 |
COX-2 inhibitors and cardiovascular risk.
Topics: Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; | 2007 |
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase | 2007 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cerebrovascular Disorders; Coronar | 2006 |
Cardiovascular disease in patients with spondyloarthropathies.
Topics: Antirheumatic Agents; Atherosclerosis; Atrioventricular Block; Cardiovascular Diseases; Comorbidity; | 2008 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C | 2002 |
Considerations for the safe prescribing and use of COX-2-specific inhibitors.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2002 |
5 trials available for rofecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
Topics: Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Data Interpretation, Sta | 2008 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Topics: Adenoma; Aged; Cardiovascular Diseases; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclooxygenase | 2007 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
105 other studies available for rofecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act.
Topics: Arthritis; Cardiovascular Diseases; Chronic Pain; Hemophilia A; Humans; Lactones; Orphan Drug Produc | 2019 |
Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats.
Topics: Administration, Oral; Age Factors; Amino Acids; Animals; Aorta; Arterial Pressure; Cardiovascular Di | 2013 |
The Vioxx® legacy: Enduring lessons from the not so distant past.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; History, 21st Century; Humans; | 2014 |
Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Male; Meta-Analysis as Topic | 2017 |
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2008 |
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; D | 2008 |
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Dr | 2009 |
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; C | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Topics: Aged; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Util | 2009 |
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Topics: Animals; Biomarkers; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Cyc | 2010 |
Persistence of cardiovascular risk after rofecoxib discontinuation.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Administration S | 2010 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase | 2012 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu | 2002 |
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S | 2002 |
Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2002 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Matters of the heart: assessing the cardiovascular safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2003 |
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Ethics Committees, Research; Huma | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2004 |
Unnecessary withdrawal of Vioxx.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Drug Approval; Humans; Lactones; Sulfones | 2004 |
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmark | 2004 |
COX-2-derived prostacyclin confers atheroprotection on female mice.
Topics: Animals; Antioxidants; Arteriosclerosis; Cardiovascular Diseases; Cells, Cultured; Cyclooxygenase 2; | 2004 |
Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal.
Topics: Canada; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Liabili | 2004 |
Vioxx risk could signify trouble in class.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2004 |
[Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; | 2004 |
[Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi | 2004 |
Public interest group accuses FDA of trying to discredit whistleblower.
Topics: California; Cardiovascular Diseases; Consumer Organizations; Lactones; Sulfones; United States; Unit | 2004 |
A world without Vioxx: to COX-2 or not to COX-2?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2004 |
[The case of Vioxx requires consideration].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug In | 2004 |
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2004 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug Approval; Humans; Lactones; R | 2004 |
[MSD about Vioxx--important to learn from the experience without hindsight].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug In | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; History, 20th Cent | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; His | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact | 2004 |
[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Gastrointestinal Diseas | 2004 |
[Rofecoxib--a recall with implications].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Humans; | 2004 |
Under surveillance.
Topics: Biotechnology; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Hum | 2005 |
Sentinel systems are needed for long term adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Approv | 2005 |
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs a | 2005 |
VIOXX and cardiovascular events: a class effect?
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Randomized Controlled Trials a | 2005 |
Coxibs and caution.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Sulfones | 2005 |
Don't throw out the baby with the bathwater!
Topics: Advertising; Cardiovascular Diseases; Child; Child Welfare; Clinical Trials as Topic; Cyclooxygenase | 2005 |
COX-2 inhibitors: cancer prevention or cardiovascular risk?
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
[Vioxx: reasons for a premature retirement].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
The withdrawal of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy | 2005 |
The lessons of Vioxx.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Factors associated with celecoxib and rofecoxib utilization.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; | 2005 |
Cyclooxygenase-2 inhibitors and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Canada; Cardiovascular Diseases; Celecoxib; Cycl | 2005 |
COX-2 inhibitors--first, do no harm.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Humans; Lactones; New | 2005 |
[VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Sulfones | 2005 |
COX-2 inhibitors and cardiovascular toxicity: a class effect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Raising the safety bar--the FDA's coxib meeting.
Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular | 2005 |
Learning the value of drugs--is rofecoxib a regulatory success story?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug In | 2005 |
Institutional review boards must conduct safety review.
Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Clinical Trials Data Monitoring Commit | 2005 |
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; F | 2005 |
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Topics: Antirheumatic Agents; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase Inhibitors; D | 2005 |
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Comorbidity; Cyclooxyge | 2005 |
Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2005 |
Cardiovascular risk associated with celecoxib.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Hum | 2005 |
Painkiller verdict shows mistrust of Merck.
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Disclosure; Drug Industry; Humans; Lactones; Male; Su | 2005 |
The Vioxx debacle revisited.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Physician's Rol | 2005 |
The Vioxx debacle revisited.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmark | 2005 |
The lessons of Vioxx.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug In | 2005 |
Journal grows suspicious of Vioxx data.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Drug Industry; Humans; Lactones; Periodicals as T | 2005 |
Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
Topics: Authorship; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Databases, | 2005 |
[Role of cyclo-oxygenases in the effects of angiotensin II].
Topics: Angiotensin II; Animals; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lacton | 2006 |
Expression of concern reaffirmed.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D | 2006 |
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
[Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; | 2006 |
The patient's perspective on the recall of Vioxx.
Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control | 2006 |
Adverse cardiovascular effects of rofecoxib.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lact | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Stu | 2006 |
Adverse cardiovascular effects of rofecoxib.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lact | 2006 |
How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Edito | 2006 |
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; Humans; Lactones; Practice Patt | 2006 |
[Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Confidence Intervals; Controlled Clinical Trials | 2006 |
[How many harmed by rofecoxib in Germany?].
Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Confidence Intervals; Controlled Clin | 2006 |
[Overestimated].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi | 2006 |
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cycloo | 2007 |
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxy | 2006 |
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib | 2007 |
Cardiac risks with COX-2 inhibitors.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Dose-Res | 2007 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Bas | 2005 |
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxi | 2007 |
Man on a mission.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans; | 2007 |
A proposed fairer method for conducting rofecoxib trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2007 |
Keeping science on top in drug evaluation.
Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfe | 2007 |
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Stud | 2008 |
Merck's Careful Study of Vioxx.
Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Treatment Outcome | 2008 |
Rofecoxib (Vioxx): a year in review.
Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans; | 2001 |
Celecoxib-- the debate ranges on.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Cover | 2001 |
Pain relief at a price. A blow to the heart?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |